TDP-43 phase separation therapeutics for ALS-FTD

Analysis: SDA-2026-04-01-gap-006 | Domain: neurodegeneration | Date: 2026-04-01 | 7 hypotheses | 0 KG edges | Autonomous Agent

Hypotheses

#HypothesisTargetScorePrice
#1 Heat Shock Protein 70 Disaggregase Amplification HSPA1A 0.645 $0.65
Targeted upregulation of HSP70 family members (HSPA1A, HSPA8) with HSP40 co-chaperones to actively disaggregate pathological TDP-43 condensates...
#2 PARP1 Inhibition Therapy PARP1 0.634 $0.63
Use FDA-approved PARP1 inhibitors to prevent TDP-43 recruitment to DNA damage sites and reduce cytoplasmic mislocalization...
#3 Arginine Methylation Enhancement Therapy PRMT1 0.621 $0.62
Pharmacological enhancement of PRMT1/CARM1 activity to reduce TDP-43 RNA-binding avidity and prevent pathological phase separation...
#4 RNA Granule Nucleation Site Modulation G3BP1 0.575 $0.57
Selective inhibition of G3BP1/G3BP2 to prevent TDP-43 recruitment to pathological stress granules...
#5 Glycine-Rich Domain Competitive Inhibition TARDBP 0.531 $0.53
Engineered peptide mimetics to competitively inhibit TDP-43 intermolecular interactions through the glycine-rich domain...
#6 Serine/Arginine-Rich Protein Kinase Modulation SRPK1 0.519 $0.52
Modulation of SRPK1/CLK1 to alter splicing regulator phosphorylation and reduce TDP-43 multivalent RNA interactions...
#7 Low Complexity Domain Cross-Linking Inhibition TGM2 0.500 $0.50
Selective TGM2 inhibition to prevent TDP-43 cross-linking and maintain dynamic condensate properties...